catalyst dictat downgrad hold
impress term recent broad collabor gilead drive pt
crystallis signific part discoveri platform valu
posit deal provid extern endors glpg burgeon
pipelin commerci partner secur cash rapidli advanc toledo
howev recent stock uptick leav insuffici upsid coupl
lack major near-term catalyst dictat downgrad hold
global gilead deal impress endors return up-front
equiti invest gilead gain exclus ex-eu right glpg current
futur programm essenti secur independ next decad
provid fund acceler pipelin notabl toledo establish
eu commerci presenc ahead potenti filgotinib launch view
deal equiti premium paid welcom endors glpg pipelin
platform albeit recognis year standstil effect remov acquisit
option stock flexibl execut futur ww out-licens deal
buy rate sinc initi sep valuat plu major
near-term catalyst dictat hold
multi-blockbust potenti filgotinib importantli compar efficaci
best class safeti avoid typic thrombot event associ jaki
class filgotinib could consid better risk benefit profil
jaki differenti safeti profil potenti key drive use
phase ii data sjgren syndrom form lupu could support view
broad commerci potenti phase psoriat arthriti start ye
potenti also ankylos spondyl
ra file us eu japan due forecast ww peak sale
filgotinib ra crohn diseas ulcer coliti
cumul contribut indic adjust revis
cost-shar lower filgotinib npv retain
fund rapidli advanc pipelin expect signific proport
use acceler glpg secret toledo programm phase ii trial
plan run parallel next year maximis first-mov advantag
undisclos mechan action phase isabela trial lung
fibrosi ipf interim futil analysi around data
phase ii system sclerosi data rais probabl
endors boost npv assum
ww peak sale ipf launch data phase iib rocella trial
osteoarthr expect forecast ww peak sale
npv probabl servier ex-u right glpg seek
bring least compound clinic annual cours agreement
financi immateri cash burn outlook unchang
exclud proce gilead deal in-lin
price pt
price pt
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
lead product filgotinib underpin much
valuat remain focu encourag
competit profil phase finch
ra programm phase ii fitzroy crohn trial
partner gilead maximis commerci
numer pipelin programm could also
crystallis valu via possibl mileston
broad opt-in allianc gilead particular
lung fibrosi ipf osteoarthr howev
find insuffici upsid current share price
along lack signific near-term
stock-mov catalyst dictat hold
compris filgotinib
posit filgotinib data crohn ulcer
posit phase ii iguana result atop
dermat could worth around
posit phase isabela result
potenti catalyst could boost npv
deriv price per share/ad
safeti concern filgotinib could remov around
valuat
efficaci and/or safeti concern filgotinib
phase crohn ulcer coliti trial could
remov valuat
setback delay could remov
efficaci safeti concern ipf
could remov least
setback could reduc npv deriv price
per share/ad
june along
proce gilead deal
suffici fund oper forese
commercialis europ
orphan diseas ipf could provid potenti
partner gilead success file filgotinib us
fda along eu japan file
respect approv ra
phase ii filgotinib sjgren cutan lupu
data respect
galapago day novemb focus
toledo programm potenti includ initi
phase data gen candid
data potenti file
phase ii iguana data atop dermat
pleas see import disclosur inform page report
price downgrad hold
lack nt stock move catalyst
lead product filgotinib along cash underpin major sum-
of-the-part valuat remain focu investor gilead licens global right
decemb provid partner maximis drug commerci potenti
abbvi elect opt-out favour prioritis jak inhibitor upadacitinib
encourag filgotinib competit profil base phase iib darwin
phase finch rheumatoid arthriti ra clinic data result phase
ii fitzroy trial also suggest drug effect inflammatori bowel diseas
ibd forecast global blockbust potenti larg compris ra
recent broad collabor gilead provid extern endors
galapago larg underappreci pipelin discoveri capabl gilead
gain opt-in ex-eu right programm post-phas ii pivot
programm lung fibrosi ipf underway could signific
commerci potenti phase ii prepar phase
indic partner servier osteoarthr out-
licens atop dermat could also underappreci phase ii asset
view gilead collabor fund like use acceler develop
secret toledo programm aim secur glpg first-mov advantag
howev find insuffici upsid current share price along
lack signific near-term stock-mov catalyst dictat downgrad hold
safeti profil filgotinib
select inhibitor filgotinib promis safe conveni oral treatment
rheumatoid arthriti ra encourag phase ii data crohn diseas cd suggest
drug could also potenti ibd perhap greater unmet medic need
albeit smaller elig patient popul multipl proof-of-concept studi
indic on-going compar current approv biolog agent tnf
 humira filgotinib administ oral target specif rapid
onset sustain respons potenti monotherapi use
sale forecast ra cd ulcer coliti
uc cumul contribut indic
valuat per share probabl success
news flow plan us eu japan file ra potenti
approv potenti updat time manta male safeti
studi phase ii data sjogren syndrom cutan lupu
us file confirm suggest manta rate-limit step
recal fda allow use highest filgotinib dose us site
phase iib darwin trial basi regulatori concern male reproduct
system base rat/dog toxicolog studi thu fda allow inclus
mg/day dose finch programm import posit view
understand darwin trial confirm clinic meaning chang male
hormon level includ ex-u patient finch programm
also includ dedic phase ii male patient testicular safeti studi manta
could final lay safeti concern rest view
note differ fda divis approv phase divers studi cd
phase iib/iii select studi uc patient trial enrol us male
pleas see import disclosur inform page report
elig receiv higher dose fail least one prior
earli juli partner gilead announc follow discuss fda discuss
total exist filgotinib dataset establish path forward us nda
file filgotinib specif fda requir regard data
manta studi outlin time avail data
manta nevertheless posit outcom appear full manta data
may rate limit step us file
forecast peak sale ra cd uc understand
gilead galapago aim pursu develop filgotinib indic
includ crohn sub-popul given extens programm includ
ww peak sale contribut reflect filgotinib potenti use indic
beyond ra ibd note humira first anti-tnf biolog approv
commerci success part due regulatori approv
numer indic current believ humira global sale
use indic ra ibd henc estim contribut
diseas filgotinib repres around peak
galapago receiv unchang tier royalti sale partner gilead
retain profit-shar co-promot benelux galapago
still elig receiv mileston depend
achiev sale target howev part broad collabor gilead
galapago respons fund spend
pleas see import disclosur inform page report
gilead option exclus ex-european right galapago
current futur programm except novarti
world-wide right galapago respons discoveri develop
programm end phase ii follow gilead right opt-in
co-develop cost share equal except
gilead pay opt-in per programm galapago
elig tier royalti rang
novel mechan action fibrosi
sale forecast ww ipf assum launch
valuat per share probabl success
news flow phase iia novesa system sclerosi data phase
isabela ipf futil analysi like efficaci data
phase iia idiopath pulmonari fibrosi ipf flora data encourag
importantli signal suggest may stabilis lung function
confirm on-going isabela studi could signific benefit given
current approv drug esbriet pirfenidon ofev nintedanib slow rate
diseas progress autotaxin inhibitor orphan drug design
ipf us europ
phase isabela programm initi decemb consist two
ident double-blind placebo-control trial evalu two dose
once-daili top standard care pirfenidon nintedanib prior
versu placebo top standard care month primari endpoint
rate forc vital capac fvc declin month secondari endpoint
includ respiratory-rel hospitalis overal surviv qualiti life safeti
futil analysi perform patient complet month
treatment expect occur data expect
galapago split global develop cost gilead elig
mileston potenti us fda approv royalti
us sale forecast ww peak sale base modest penetr
mild-moder ipf patient note sale esbriet ofev combin
around two year us market
ipf core area focu galapago antagonist current
phase iia pinta trial data preclin develop
also phase ii novesa trial system sclerosi ssc
first data expect given high-risk indic current
ascrib valu ssc
high-risk potenti high-reward
sale forecast ww osteoarthr assum launch servier
valuat per share probabl success
news flow phase ii rocella data trigger gilead opt-in decis
novel potent select oral inhibitor develop
osteoarthr oa adamt disintegrin metalloproteinas
thrombospondin motif enzym particular implic
degrad aggrecan aggrecan core compon articular cartilag
pleas see import disclosur inform page report
extracellular matrix key cartilag function increas aggrecanas activ
initi loss aggrecan recognis trigger factor oa preced
sever cartilag destruct characterist oa
phase trial safe well-toler importantli also shown
lead dose-depend reduct blood level arg neoepitop fragment
week period arg biomark cartilag breakdown releas
cleavag aggrecan
phase iib rocella trial initi june evalu three once-daili oral
dose versu placebo patient knee oa week
primari endpoint chang cartilag thick week assess
qmri imag central medial tibiofemor compart recruit complet
around six month ahead schedul june headlin data expect
discov part oa allianc galapago servier
servier exercis ex-u option juli complet rocella
studi gilead option pay us right plu addit
certain endpoint met regulatori
commerci mileston galapago contribut develop cost
us current forecast ww peak sale npv probabl
grant fda track design novemb
valuat current ascrib valu programm given earli
stage develop
news flow novemb day highlight toledo potenti includ initi
phase data start phase
toledo programm aim improv upon diseas control rate achiev
current standard care applic across number inflammatori diseas
programm employ novel mechan action target interplay
dendrit sensori cell epitheli cell preclin data number
inflammatori bowel diseas ibd model rheumatoid arthriti ra model
suggest substanti reduct diseas activ index superior drug
galapago plan start phase ii first gener toledo compound
ulcer coliti despit undisclos toxic
prevent oral system deliveri galapago expect second
gener compound better toler data plan
phase trial confirm preclin profil enabl develop broader rang
inflammatori diseas target like reveal upon phase ii initi
manag keen maintain develop timelin advantag plan
eight proof-of-concept phase ii studi could dose-
galapago enthusiast programm like focu
novemb day toledo biggest discoveri project around
chemist diseas model scientist dedic class perhap
develop budget alloc
pleas see import disclosur inform page report
hike price
per share/ad price base sum-of-the-part valuat
larg probability-adjust npv filgotinib ipf
osteoarthr atop dermat cf partnership togeth net
exhibit galapago sourc potenti upsid downsid risk
pleas see import disclosur inform page report
peakvalueadj valueeurindicationsal mn eurmn prob eurmn per sharefilgotinibra crohn ulcer coliti collaborationcyst pulmonari dilut fundingmin yr dilut sharedownsidep sharefilgotinib regulatori approv ramajor approv phase crohn ulcer colitisposit data confirm and/or safeti phase ii iguana atop dermatitisposit efficaci phase isabela ipfposit efficaci and/or safeti exhibit galapago catalyst
pleas see import disclosur inform page report
